Volume | 499,221 |
|
|||||
News | - | ||||||
Day High | 11.50 | Low High |
|||||
Day Low | 10.79 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Olema Pharmaceuticals Inc | OLMA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.21 | 10.79 | 11.50 | 11.32 | 11.20 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
6,805 | 499,221 | $ 11.22 | $ 5,603,729 | - | 3.00 - 17.7911 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:29:44 | 7 | $ 10.86 | USD |
Olema Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
632.95M | 55.91M | - | 0 | -104.79M | -1.87 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Olema Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OLMA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.82 | 11.85 | 10.78 | 11.22 | 712,149 | -0.50 | -4.23% |
1 Month | 13.12 | 15.32 | 10.65 | 12.17 | 1,120,680 | -1.80 | -13.72% |
3 Months | 13.68 | 16.775 | 10.65 | 12.77 | 831,995 | -2.36 | -17.25% |
6 Months | 13.08 | 17.7911 | 9.96 | 13.05 | 798,932 | -1.76 | -13.46% |
1 Year | 3.44 | 17.7911 | 3.00 | 11.71 | 559,959 | 7.88 | 229.07% |
3 Years | 30.65 | 36.70 | 2.00 | 11.69 | 420,791 | -19.33 | -63.07% |
5 Years | 47.00 | 60.27 | 2.00 | 13.12 | 393,951 | -35.68 | -75.91% |
Olema Pharmaceuticals Description
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. |